Guía de práctica clínicaV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pyloriV Spanish Consensus Conference on Helicobacter pylori infection treatment☆
Section snippets
Introducción
La infección por Helicobacter pylori (H. pylori) afecta a alrededor del 50% de la población mundial y desempeña un papel fundamental en el desarrollo de diversas enfermedades digestivas como la gastritis crónica, la úlcera péptica y el cáncer gástrico, por lo que un diagnóstico adecuado y un tratamiento eficaz son esenciales en la práctica clínica. En España, se han organizado hasta la fecha cuatro reuniones de consenso sobre la infección por H. pylori: en 19991, 2, 20043, 4, 20125 y, la
Metodología
Participantes en el consenso: se invitó a participar a los investigadores españoles que durante los últimos 5 años hubieran publicado al menos 5 artículos sobre el tratamiento de la infección por H. pylori, identificados mediante la estrategia de búsqueda «Helicobacter pylori AND Spain» en PubMed. En total, 14 expertos fueron invitados, y todos ellos aceptaron, incluyendo gastroenterólogos, médicos de Atención Primaria y expertos en metodología científica y medicina basada en la evidencia. Un
Recomendaciones
Cada recomendación se acompaña del resultado de la votación (porcentaje de acuerdo), el grado de recomendación (GR; fuerte o débil), la calidad de la evidencia (CE; alta, moderada, baja o muy baja) y de la discusión de la evidencia correspondiente.
Todas las recomendaciones aprobadas en el presente consenso español sobre el tratamiento de la infección por H. pylori se incluyen en la tabla 1. Los fármacos, la duración y la dosis de cada uno de los componentes de las pautas recomendadas se
Conflicto de intereses
J. Alcedo, J. Amador, L. Bujanda, X. Calvet, M. Castro-Fernández, E. Gené, A. Lanas, A.J. Lucendo, J. Molina-Infante, A. Pérez-Aisa e I. Puig declaran no tener ningún conflicto de intereses.
L. Fernández-Salazar actividad docente: Janssen, Norgine, Salvat, Tillots.
J.P. Gisbert asesoramiento científico, soporte para investigación o actividades formativas: Mayoly, Allergan, Diasorin, Gebro Pharma, Richen.
O.P. Nyssen soporte para investigación: Mayoly, Allergan.
Bibliografía (264)
- et al.
[Treatment for the eradication of Helicobacter pylori, Recommendations of the Spanish Consensus Conference]
Med Clin (Barc)
(2000) - et al.
[III Spanish Consensus Conference on Helicobacter pylori infection]
Gastroenterol Hepatol
(2013) - et al.
[IV Spanish Consensus Conference on Helicobacter pylori infection treatment]
Gastroenterol Hepatol
(2016) - et al.
[How can we find, design, evaluate and use clinical practice guidelines?.]
Gastroenterol Hepatol
(2008) Experimental Study of Group Opinion-Delphi Method
Features
(1969)[Rescue therapy after Helicobacter pylori eradication failure]
Gastroenterol Hepatol
(2011)- et al.
[Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]
Gastroenterol Hepatol
(2013) - et al.
[10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]
Gastroenterol Hepatol
(2016) - et al.
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]
Med Clin (Barc)
(2016) - et al.
Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial
Gastroenterol Hepatol
(2017)
Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study
Gastroenterol Hepatol
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial
Lancet
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial
Lancet
How to effectively use bismuth quadruple therapy: The good, the bad, and the ugly
Gastroenterol Clin North Am
Retrospective analysis of the use of quadruple therapy with bismuth (Pylera((R))) in real-life clinical practice in Spain
Gastroenterol Hepatol
Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice
Gastroenterol Hepatol
Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy
Gastroenterol Hepatol
Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis
Microb Pathog
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
Clin Gastroenterol Hepatol
[Helicobacter pylori infection, The Spanish consensus report. The Spanish Consensus Conference Group]
Rev Esp Enferm Dig
Indications, diagnostic tests and Helicobacter pylori eradication therapy Recommendations by the 2 nd Spanish Consensus Conference
Rev Esp Enferm Dig
[Eradication treatment of Helicobacter pylori, Recommendations of the II Spanish Consensus Conference]
Med Clin (Barc)
Grading quality of evidence and strength of recommendations
BMJ
Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines
Can J Gastroenterol Hepatol
Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection
J Antimicrob Chemother
Systematic review: third-line susceptibilityguided treatment for Helicobacter pylori infection
Ther Adv Gastroenterol
Empirical or susceptibility-guided treatment for Helicobacter pylori infection?. A comprehensive review
Therap Adv Gastroenterol
Empirical versus susceptibility-guided treatment of Helicobacter pylori infection: a meta-analysis
United European Gastroenterol J
Helicobacter pylori “Test-and-Treat” strategy with urea breath test: A cost-effective strategy for the management of dyspepsia and the prevention of ulcer and gastric cancer in Spain-Results of the Hp-Breath initiative
Helicobacter
Kyoto global consensus report on Helicobacter pylori gastritis
Gut
Current European concepts in the management of Helicobacter pylori infection--the Maastricht Consensus Report, The European Helicobacter Pylori Study Group (EHPSG)
Eur J Gastroenterol Hepatol
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report
Aliment Pharmacol Ther
Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report
Gut
Management of Helicobacter pylori infection--the Maastricht IV/Florence Consensus Report
Gut
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence
Clin Gastroenterol Hepatol
Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies
Helicobacter
Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions
Gastroenterology
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
Gut
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens
Helicobacter
Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community
Gut
Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough
Aliment Pharmacol Ther
First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial
J Antimicrob Chemother
Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions
Eur J Gastroenterol Hepatol
As Scientific Committee of the Hp-Eureg on Behalf of the National C Protocol of the European Registry on the management of Helicobacter pylori infection (Hp-EuReg)
Helicobacter
European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
Antibiotics (Basel)
Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg)
J Clin Gastroenterol
Spanish primary care survey on the management of Helicobacter pylori infection and dyspepsia: Information, attitudes, and decisions
Helicobacter
Review article: potassium-competitive acid blockers for the treatment of acid-related disorders
Aliment Pharmacol Ther
Effectiveness and safety of vonoprazan versus proton pump inhibitors for second-line Helicobacter pylori eradication therapy: Systematic review and meta-analysis
Digestion
Efficacy and safety of vonoprazan-based versus proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials
Biomed Res Int
Cited by (18)
Helicobacter pylori infection is associated with decreased odds for eosinophilic esophagitis in Mexican patients
2024, Gastroenterologia y HepatologiaPeptic ulcer
2023, Medicina ClinicaSurveillance of Helicobacter pylori resistance over 22 Years (2000-2021) in Northern Spain
2023, Journal of Global Antimicrobial Resistance
- ☆
Este documento se publica simultáneamente en las revistas Gastroenterología y Hepatología – [https://doi.org/10.1016/j.gastrohep.2021.07.011] y Revista Española de Enfermedades Digestivas – [https://doi.org/10.17235/reed.2021.8358/2021], con el consentimiento de los autores y editores.